

NIKPHARM LTD
UNAUDITED ABRIDGED FINANCIAL STATEMENTS
FOR THE PERIOD 9 MAY 2022 TO 31 MAY 2023

Ballantyne & Co
Chartered Accountants & Registered Auditors
60 St. Enoch Square
Glasgow
G1 4AG

NikPharm Ltd
Unaudited Financial Statements
For the Period 9 May 2022 to 31 May 2023

Contents

	Page
Abridged Balance Sheet	1—2
Notes to the Abridged Financial Statements	3

NikPharm Ltd
Abridged Balance Sheet
As At 31 May 2023

Registered number: 14093037

		31 May 2023	
	Notes	£	£
FIXED ASSETS			
Tangible Assets	4		596,029
			<hr/>
			596,029
CURRENT ASSETS			
Debtors		120	
Cash at bank and in hand		156	
		<hr/>	
		276	
Creditors: Amounts Falling Due Within One Year		<hr/>	(188,312)
NET CURRENT ASSETS (LIABILITIES)			<hr/> (188,036)
TOTAL ASSETS LESS CURRENT LIABILITIES			<hr/> 407,993
Creditors: Amounts Falling Due After More Than One Year			<hr/> (432,188)
NET LIABILITIES			<hr/> (24,195)
CAPITAL AND RESERVES			
Called up share capital	6	120	
Profit and Loss Account		(24,315)	
		<hr/>	
SHAREHOLDERS' FUNDS			<hr/> (24,195)

NikPharm Ltd
Abridged Balance Sheet (continued)
As At 31 May 2023

For the period ending 31 May 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

All of the company's members have consented to the preparation of an Abridged Balance Sheet for the year end 31 May 2023 in accordance with section 444(2A) of the Companies Act 2006.

On behalf of the board

Mr Mohammad Reza Danesh Azari

Director

20 October 2023

The notes on page 3 form part of these financial statements.

NikPharm Ltd
Notes to the Abridged Financial Statements
For the Period 9 May 2022 to 31 May 2023

1. General Information

NikPharm Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 14093037. The registered office is 5 Midfield Parade, Mayplace Road East, Bexleyheath, Kent, DA7 6NA.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Going Concern Disclosure

The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.

2.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold

NIL

3. Average Number of Employees

Average number of employees, including directors, during the year was as follows: NIL

4. Tangible Assets

	Total
	£
Cost	
As at 9 May 2022	-
Additions	596,029
As at 31 May 2023	596,029
Net Book Value	
As at 31 May 2023	596,029
As at 9 May 2022	-

5. Secured Creditors

Of the creditors the following amounts are secured.

	31 May 2023
	£
Bank loans and overdrafts	445,688

6. Share Capital

	31 May 2023
	£
Allotted, Called up and fully paid	120

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.